Prophase Labs Inc Stock Price, News & Analysis

ABL Diagnostics reports that its controlling shareholder ABL S.A. and ProPhase Labs (Nasdaq: PRPH) have signed a non-binding letter of intent for a proposed reverse merger under which ABL would become the majority owner of the combined company.

The LOI is preliminary, creates no obligation to close, and is subject to due diligence, definitive agreements, regulatory approvals, and Nasdaq listing requirements. The parties target an indicative 60–90 day timeframe to execute definitive agreements. ABL S.A.’s control over ABL Diagnostics is unchanged and the proposal does not trigger the mandatory offer threshold based on available information.

The transaction may require ProPhase shareholder approval in the U.S. if a change of control occurs or if an issuance reaches 20% or more. The release is treated as inside information and will be archived for at least 5 years.

ProPhase Labs (NASDAQ: PRPH) will host an exclusive investor webinar on December 1, 2025 at 4:15 p.m. ET, hosted by RedChip Companies and featuring Chairman & CEO Ted Karkus.

The presentation will review ProPhase’s portfolio across molecular diagnostics, genomics, and consumer health, recent milestones including U.S. patent approval and clinical validation of the BE-Smart™ Esophageal Cancer Test, and a stated $7–14 billion addressable market for that test. Management will discuss a strategic initiative with Crown Medical Collections to recover more than $50 million in COVID-19 receivables, a streamlined cost structure, and the consumer genomics business Nebula Genomics with a large, diverse DNA dataset.

Planned near-term catalysts noted include commercialization of BE-Smart™ and expansion of DNA Complete® and DNA Expand™ product lines; a live Q&A follows. Registration is free via the RedChip webinar link.

ProPhase Labs (NASDAQ: PRPH) reported third-quarter 2025 results and announced strategic initiatives on November 19, 2025.

Key points: Q3 revenue $0.9M vs $1.4M year‑ago; net loss $6.8M or $(0.16) per share; cash $405,000; working capital deficit $47.5M. The company is pursuing M&A discussions, a $50M+ Crown Medical collections initiative entering settlement and litigation phases, commercialization of the BE‑Smart™ esophageal cancer test following a Mayo Clinic validation publication, and says Nebula Genomics is now profitable on a pro‑forma basis.

Management will present to shareholders today, November 19, 2025 at 2:00 p.m. ET via a virtual non‑deal roadshow.

ProPhase Labs (NASDAQ: PRPH) reminds shareholders of record as of Oct 20, 2025 to vote ahead of the Special Meeting on Nov 24, 2025 at 10:00 a.m. ET (in person at 273 Merrick Road, Lynbrook, NY).

Shareholders should submit votes before the proxy deadline of 11:59 p.m. ET on Nov 23, 2025. The board recommends voting FOR all proposals to enable strategic initiatives and actions to maintain Nasdaq listing compliance; the definitive proxy is available on the SEC EDGAR site.

ProPhase Labs (NASDAQ: PRPH) announced publication of a peer‑reviewed study in Clinical and Translational Gastroenterology validating BE‑Smart, an 8‑protein, mass‑spectrometry proteomic assay for risk stratification in Barrett’s Esophagus. Key clinical findings include 100% sensitivity for patients who later developed esophageal adenocarcinoma, overall AUC 0.75, independent test cohort AUC 0.89, and AUC 1.0 for progressors within three years. The study reports a hazard ratio 66.1 (p=0.00012) for high‑risk vs low‑risk patients. BE‑Smart requires as little as one‑tenth the tissue of legacy assays and works on standard formalin‑fixed, forceps or brush biopsy samples. Early access and physician onboarding are expected in early 2026.

ProPhase Labs (NASDAQ: PRPH) engaged RedChip Companies on October 28, 2025 to lead investor relations as the company advances commercialization and recovery initiatives. Key company priorities cited include the imminent commercialization of BE-Smart™ (esophageal cancer diagnostic), expansion of the Nebula Genomics platform, and the Crown Medical Collections initiative targeting over $50 million in near-term recoveries. RedChip will use digital distribution, webinars, roadshows, and its Small Stocks, Big Money™ program; Renmark will continue hosting quarterly earnings calls and retail virtual non-deal roadshows.

ProPhase Labs (NASDAQ: PRPH) will participate in the ThinkEquity Conference on October 30, 2025 at the Mandarin Oriental Hotel in New York.

Ted Karkus, CEO and Chairman, will present at 11:00 AM ET on October 30 and will hold one-on-one investor meetings throughout the day. Interested investors can register and schedule meetings via the provided registration link, and the presentation will be live-streamed at the supplied webcast URL.

ProPhase Labs (NASDAQ: PRPH) announced that a pivotal study validating the BE-Smart esophageal cancer proteomic test was accepted for publication in Clinical Gastroenterology and Hepatology on October 22, 2025. The study reported 100% sensitivity in a blinded cohort of 100 patients and strong discriminative performance (AUC 0.89–1.0) in independent test cohorts. ProPhase is advancing regulatory preparations, scaling laboratory capacity, and planning a phased commercial rollout beginning in 2026. Management cites a U.S. addressable market of roughly $7–$14 billion tied to ~7 million annual upper endoscopies for GERD and BE surveillance.

ProPhase Labs (NASDAQ: PRPH) announced that its three COVID-19 testing laboratory subsidiaries have filed for Chapter 11 bankruptcy reorganization. This strategic move is part of the Crown Medical Collections initiative to recover an estimated $50 million in unpaid claims from insurance companies.

The bankruptcy filing is limited to the COVID-19 lab testing units and does not affect the parent company or other subsidiaries. Crown Medical anticipates potential Q4 collections that could be multiples of the company's current market capitalization. The company continues to advance other initiatives, including the development of the BE-Smart™ esophageal cancer test, and operations at Nebula Genomics and DNA Complete subsidiaries.